Sign in

CIK 0001479419

  • Non-accelerated filer
  • Smaller reporting company

KALA BIO, Inc.

Sign in to watch
Ticker
KALA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
270604595
Phone
+1 781-996-5252
Business address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
Former names
KALA BIO, Inc., Kala Pharmaceuticals, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2018-06-12 Paull Robert Bradley Director Grant or award · Stock Option (right to buy) +12,960 12,960
2018-06-12 Rosen Howard B Director Grant or award · Stock Option (right to buy) +12,960 12,960
2018-06-11 Paull Robert Bradley Director Other acquisition +477 1,074
2018-05-18 Paull Robert Bradley Director Other acquisition +597 597
2018-04-05 Trachtenberg Eric General Counsel and Secretary Grant or award · Stock Option (right to buy) +150,000 150,000
2018-02-28 PERRY GREGORY D Director Grant or award · Stock Option (right to buy) +25,920 25,920
2018-02-28 Chen Hongming Chief Scientific Officer Exercise or conversion +4,000 $2.30 $9K 50,080
2018-02-28 Chen Hongming Chief Scientific Officer Exercise or conversion +5,769 $2.24 $13K 55,849
2018-02-28 Chen Hongming Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −4,000 106,236
2018-02-28 Chen Hongming Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −5,769 0
2018-02-08 ORBIMED ADVISORS LLC 10% owner Purchase +25,000 $12.93 $323K 3,447,840
2018-02-07 Bazemore Todd Chief Operating Officer Grant or award · Stock Option (right to buy) +25,000 25,000
2018-02-07 Iwicki Mark T Chief Executive Officer Grant or award · Stock Option (right to buy) +230,000 230,000
2018-02-07 Brazzell Romulus K Chief Medical Officer Grant or award · Stock Option (right to buy) +70,000 70,000
2018-02-07 Chen Hongming Chief Scientific Officer Grant or award · Stock Option (right to buy) +70,000 70,000
2018-02-07 Reumuth Mary Chief Financial Officer Grant or award · Stock Option (right to buy) +70,000 70,000
2018-02-07 LaRussa Michele Sr. VP, Regulatory and Quality Grant or award · Stock Option (right to buy) +8,000 8,000
2018-02-02 ORBIMED ADVISORS LLC 10% owner Purchase +37,840 $14.73 $557K 3,422,840
2018-02-01 ORBIMED ADVISORS LLC 10% owner Purchase +22,840 $14.99 $342K 3,385,000
2018-01-31 ORBIMED ADVISORS LLC 10% owner Purchase +339,400 $15.00 $5.1M 3,362,160

Page 20 of 24 · 472 trades